Hydroxyurea (Hydroxycarbamide; HU) is commonly used for the long-term treatment of patients with Philadelphia-chromosome negative chronic myeloproliferative neoplasms (MPNs). It is considered a first-choice agent for the treatment of these disorders as underlined by the European Leukemia Net Consensus Conference [1], although it is formally approved for this indication in some countries only. The drug is reportedly well tolerated in the large majority of subjects, although systemic and/or localized toxicities have been reported. Consensus criteria for definition of "intolerance" to HU have been described;patients who develop intolerance are candidate for second-line therapy and, more recently, for investigational drugs. However, no epidemiologic information about the occurrence of the most clinically significant HU-associated adverse events is yet available. In this study, the authors report on a multicenter series of 3,411 patients who were treated with HU among which 184, accounting for 5% of total, developed significant drug-related toxicities. These data provide an estimate of the frequency and a detailed characterization of clinically significant HU-related toxicities; these information have relevance for the management of MPN patients who require second-line therapy after developing HU-related intolerance.

Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN / E. Antonioli, P. Guglielmelli, L. Pieri, M. Finazzi, E. Rumi, V. Martinelli, N. Vianelli, M. Luigia Randi, I. Bertozzi, V. De Stefano, T. Za, E. Rossi, M. Ruggeri, E. Elli, R. Cacciola, E. Cacciola, E. Pogliani, F. Rodeghiero, M. Baccarani, F. Passamonti, G. Finazzi, A. Rambaldi, A. Bosi, M. Cazzola, T. Barbui, A.M. Vannucchi. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 87:5(2012), pp. 552-554. [10.1002/ajh.23160]

Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN

M. Finazzi;E. Cacciola;A. Rambaldi;
2012

Abstract

Hydroxyurea (Hydroxycarbamide; HU) is commonly used for the long-term treatment of patients with Philadelphia-chromosome negative chronic myeloproliferative neoplasms (MPNs). It is considered a first-choice agent for the treatment of these disorders as underlined by the European Leukemia Net Consensus Conference [1], although it is formally approved for this indication in some countries only. The drug is reportedly well tolerated in the large majority of subjects, although systemic and/or localized toxicities have been reported. Consensus criteria for definition of "intolerance" to HU have been described;patients who develop intolerance are candidate for second-line therapy and, more recently, for investigational drugs. However, no epidemiologic information about the occurrence of the most clinically significant HU-associated adverse events is yet available. In this study, the authors report on a multicenter series of 3,411 patients who were treated with HU among which 184, accounting for 5% of total, developed significant drug-related toxicities. These data provide an estimate of the frequency and a detailed characterization of clinically significant HU-related toxicities; these information have relevance for the management of MPN patients who require second-line therapy after developing HU-related intolerance.
international-working-group; world-health-organization; essential thrombocythemisa; polycythemia-vera; myelofibrosis research; diagnostic-criteria; unified definition; high-risk
Settore MED/15 - Malattie del Sangue
Article (author)
File in questo prodotto:
File Dimensione Formato  
ajh.23160.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 712.84 kB
Formato Adobe PDF
712.84 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/725241
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 89
  • ???jsp.display-item.citation.isi??? 79
social impact